NASDAQ:ARAV

Aravive Competitors

$4.84
-0.25 (-4.91 %)
(As of 05/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.71
$5.24
50-Day Range
$5.05
$9.24
52-Week Range
$4.27
$14.94
Volume309,737 shs
Average Volume216,942 shs
Market Capitalization$95.15 million
P/E RatioN/A
Dividend YieldN/A
Beta3.2

Competitors

Aravive (NASDAQ:ARAV) Vs. EOLS, URGN, SPRO, VTGN, FHTX, and MEIP

Should you be buying ARAV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Aravive, including Evolus (EOLS), UroGen Pharma (URGN), Spero Therapeutics (SPRO), VistaGen Therapeutics (VTGN), Foghorn Therapeutics (FHTX), and MEI Pharma (MEIP).

Aravive (NASDAQ:ARAV) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Aravive and Evolus, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aravive01502.83
Evolus12502.50

Aravive presently has a consensus target price of $25.20, suggesting a potential upside of 420.66%. Evolus has a consensus target price of $15.00, suggesting a potential upside of 73.01%. Given Aravive's stronger consensus rating and higher possible upside, equities analysts plainly believe Aravive is more favorable than Evolus.

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. Comparatively, 21.7% of Evolus shares are owned by institutional investors. 30.5% of Aravive shares are owned by company insiders. Comparatively, 10.1% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Aravive and Evolus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AraviveN/A-47.21%-39.11%
Evolus-120.63%-121.11%-30.91%

Valuation & Earnings

This table compares Aravive and Evolus' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aravive$4.75 million20.03$-18,220,000.00($1.57)-3.08
Evolus$34.92 million10.86$-90,030,000.00($3.19)-2.72

Aravive has higher earnings, but lower revenue than Evolus. Aravive is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Aravive has a beta of 3.2, suggesting that its share price is 220% more volatile than the S&P 500. Comparatively, Evolus has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500.

Summary

Aravive beats Evolus on 11 of the 13 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Valuation & Earnings

This table compares Aravive and UroGen Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aravive$4.75 million20.03$-18,220,000.00($1.57)-3.08
UroGen Pharma$20,000.0018,849.09$-105,150,000.00($5.12)-3.52

Aravive has higher revenue and earnings than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aravive and UroGen Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AraviveN/A-47.21%-39.11%
UroGen PharmaN/A-92.22%-81.71%

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. Comparatively, 71.6% of UroGen Pharma shares are owned by institutional investors. 30.5% of Aravive shares are owned by company insiders. Comparatively, 12.0% of UroGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Aravive has a beta of 3.2, suggesting that its share price is 220% more volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Aravive and UroGen Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aravive01502.83
UroGen Pharma00303.00

Aravive presently has a consensus target price of $25.20, suggesting a potential upside of 420.66%. UroGen Pharma has a consensus target price of $40.50, suggesting a potential upside of 124.50%. Given Aravive's higher possible upside, equities analysts plainly believe Aravive is more favorable than UroGen Pharma.

Summary

Aravive beats UroGen Pharma on 10 of the 13 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Aravive and Spero Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aravive$4.75 million20.03$-18,220,000.00($1.57)-3.08
Spero Therapeutics$18.15 million20.73$-60,920,000.00($3.35)-3.81

Aravive has higher earnings, but lower revenue than Spero Therapeutics. Spero Therapeutics is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aravive and Spero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AraviveN/A-47.21%-39.11%
Spero Therapeutics-768.15%-93.43%-72.17%

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. Comparatively, 57.6% of Spero Therapeutics shares are owned by institutional investors. 30.5% of Aravive shares are owned by insiders. Comparatively, 17.4% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Aravive has a beta of 3.2, indicating that its stock price is 220% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aravive and Spero Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aravive01502.83
Spero Therapeutics00503.00

Aravive currently has a consensus price target of $25.20, suggesting a potential upside of 420.66%. Spero Therapeutics has a consensus price target of $32.75, suggesting a potential upside of 156.86%. Given Aravive's higher possible upside, research analysts plainly believe Aravive is more favorable than Spero Therapeutics.

Summary

Aravive beats Spero Therapeutics on 9 of the 13 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Aravive and VistaGen Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aravive$4.75 million20.03$-18,220,000.00($1.57)-3.08
VistaGen TherapeuticsN/AN/A$-20,770,000.00($0.50)-5.24

Aravive has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aravive and VistaGen Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AraviveN/A-47.21%-39.11%
VistaGen TherapeuticsN/AN/A-272.12%

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. Comparatively, 3.1% of VistaGen Therapeutics shares are owned by institutional investors. 30.5% of Aravive shares are owned by insiders. Comparatively, 13.7% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Aravive has a beta of 3.2, indicating that its stock price is 220% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aravive and VistaGen Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aravive01502.83
VistaGen Therapeutics00403.00

Aravive currently has a consensus price target of $25.20, suggesting a potential upside of 420.66%. VistaGen Therapeutics has a consensus price target of $5.6667, suggesting a potential upside of 116.28%. Given Aravive's higher possible upside, research analysts plainly believe Aravive is more favorable than VistaGen Therapeutics.

Summary

Aravive beats VistaGen Therapeutics on 9 of the 12 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Aravive and Foghorn Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aravive$4.75 million20.03$-18,220,000.00($1.57)-3.08
Foghorn TherapeuticsN/AN/AN/AN/AN/A

Foghorn Therapeutics has lower revenue, but higher earnings than Aravive.

Profitability

This table compares Aravive and Foghorn Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AraviveN/A-47.21%-39.11%
Foghorn TherapeuticsN/AN/AN/A

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. 30.5% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aravive and Foghorn Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aravive01502.83
Foghorn Therapeutics00403.00

Aravive currently has a consensus price target of $25.20, suggesting a potential upside of 420.66%. Foghorn Therapeutics has a consensus price target of $24.6667, suggesting a potential upside of 142.07%. Given Aravive's higher possible upside, research analysts plainly believe Aravive is more favorable than Foghorn Therapeutics.

Summary

Aravive beats Foghorn Therapeutics on 5 of the 8 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Aravive and MEI Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aravive$4.75 million20.03$-18,220,000.00($1.57)-3.08
MEI Pharma$28.91 million12.92$-46,010,000.00($0.26)-12.77

Aravive has higher earnings, but lower revenue than MEI Pharma. MEI Pharma is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aravive and MEI Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AraviveN/A-47.21%-39.11%
MEI Pharma-142.81%-33.55%-16.70%

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. Comparatively, 67.6% of MEI Pharma shares are owned by institutional investors. 30.5% of Aravive shares are owned by insiders. Comparatively, 4.4% of MEI Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Aravive has a beta of 3.2, indicating that its stock price is 220% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aravive and MEI Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aravive01502.83
MEI Pharma01602.86

Aravive currently has a consensus price target of $25.20, suggesting a potential upside of 420.66%. MEI Pharma has a consensus price target of $10.60, suggesting a potential upside of 219.28%. Given Aravive's higher possible upside, research analysts plainly believe Aravive is more favorable than MEI Pharma.


Aravive Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Evolus logo
EOLS
Evolus
1.5$8.67-2.4%$379.21 million$34.92 million-4.27Upcoming Earnings
Analyst Upgrade
Increase in Short Interest
Analyst Revision
Gap Up
UroGen Pharma logo
URGN
UroGen Pharma
1.8$18.04-3.2%$376.98 million$20,000.00-2.82News Coverage
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$12.75-0.5%$376.18 million$18.15 million-3.00Analyst Revision
News Coverage
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.3$2.62-1.5%$375.55 millionN/A-5.46Gap Down
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$10.19-1.6%$375.27 millionN/A0.00
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.32-3.6%$373.59 million$28.91 million-5.53News Coverage
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.49-7.4%$372.87 million$9.48 million-0.25
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$3.83-6.0%$372.48 million$36.63 million-4.51Upcoming Earnings
Analyst Revision
News Coverage
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$7.39-0.9%$369.07 million$72.96 million-2.39Upcoming Earnings
Analyst Downgrade
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.6$15.58-0.6%$363.05 millionN/A0.00Insider Selling
Verona Pharma logo
VRNA
Verona Pharma
1.7$6.24-1.1%$361.51 millionN/A-1.90
BCEL
Atreca
1.7$9.78-6.4%$360.21 millionN/A-3.47Upcoming Earnings
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.8$1.10-2.7%$359.16 millionN/A-0.31Upcoming Earnings
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$7.29-0.8%$357.36 million$3.89 million-3.82
Homology Medicines logo
FIXX
Homology Medicines
1.6$6.26-2.6%$357.35 million$1.67 million-2.29News Coverage
XOMA logo
XOMA
XOMA
1.5$31.26-9.6%$351.93 million$18.37 million-28.16News Coverage
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$10.24-2.6%$350.40 million$28.95 million-14.63Upcoming Earnings
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.7$10.58-4.8%$345.72 millionN/A-3.67News Coverage
Athersys logo
ATHX
Athersys
1.3$1.56-1.3%$344.48 million$5.63 million-4.22
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$5.53-0.9%$342.03 million$1.98 million-3.33News Coverage
Gap Up
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.26-0.8%$340.61 million$16.54 million-2.95Upcoming Earnings
Analyst Downgrade
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$5.27-12.9%$340.35 million$6.07 million-2.52Earnings Announcement
Analyst Upgrade
High Trading Volume
Decrease in Short Interest
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$2.98-1.7%$337.32 million$6.68 million-3.59Analyst Revision
News Coverage
Theratechnologies logo
THTX
Theratechnologies
1.1$3.57-3.1%$335.01 million$63.22 million-11.52
Cue Biopharma logo
CUE
Cue Biopharma
1.3$10.90-3.3%$332.46 million$3.46 million-6.94News Coverage
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$10.62-4.8%$321.02 million$2.71 million-18.31
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.2$3.18-7.6%$320.24 million$111.39 million22.68Analyst Report
Analyst Revision
News Coverage
Verrica Pharmaceuticals logo
VRCA
Verrica Pharmaceuticals
1.6$11.47-5.8%$315.60 millionN/A-8.69
Orphazyme A/S logo
ORPH
Orphazyme A/S
1.0$8.56-6.7%$299.19 millionN/A0.00Gap Down
ProQR Therapeutics logo
PRQR
ProQR Therapeutics
1.4$5.88-5.3%$295.21 millionN/A-4.78
BELLUS Health logo
BLU
BELLUS Health
1.7$3.75-2.7%$293.76 million$30,000.00-6.36Upcoming Earnings
Atossa Therapeutics logo
ATOS
Atossa Therapeutics
1.2$2.36-2.5%$285.15 millionN/A-1.75Upcoming Earnings
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$6.13-4.6%$284.40 million$6.29 million-3.52
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$11.80-0.9%$281.99 million$1.74 million-8.19Upcoming Earnings
News Coverage
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$5.65-6.5%$281.69 million$15.98 million-1.00Upcoming Earnings
High Trading Volume
News Coverage
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
1.6$4.07-3.7%$280.62 millionN/A-4.33Upcoming Earnings
Analyst Revision
News Coverage
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.3$2.18-5.5%$274.21 millionN/A0.00Upcoming Earnings
Kamada logo
KMDA
Kamada
1.4$6.08-0.7%$270.68 million$127.19 million12.67Upcoming Earnings
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$2.80-5.7%$269.74 million$6.01 million-2.28Earnings Announcement
News Coverage
Gap Down
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$5.45-9.9%$269.03 million$2.42 million-4.78News Coverage
Gap Down
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.6$2.99-6.0%$265.06 million$3.05 million-4.21Upcoming Earnings
News Coverage
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.50-3.3%$264.44 millionN/A-4.40High Trading Volume
Cerecor logo
CERC
Cerecor
1.8$2.76-1.4%$263.46 million$6.75 million-9.20News Coverage
Trevena logo
TRVN
Trevena
1.3$1.63-8.6%$262.88 million$30,000.00-7.09High Trading Volume
Analyst Revision
News Coverage
Immunic logo
IMUX
Immunic
1.8$11.88-19.1%$258.38 millionN/A-4.03Upcoming Earnings
News Coverage
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
1.8$1.17-2.6%$252.80 millionN/A0.00
Mustang Bio logo
MBIO
Mustang Bio
1.6$2.94-1.0%$250.41 millionN/A-2.35Upcoming Earnings
Analyst Revision
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$9.86-3.0%$250.09 millionN/A-3.73Upcoming Earnings
Unusual Options Activity
News Coverage
Immunome logo
IMNM
Immunome
1.0$22.50-7.9%$239.85 millionN/A0.00Analyst Upgrade
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.5$3.46-1.7%$234.55 millionN/A-2.45Analyst Revision
This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.